Genocea is a Cambridge, Mass.-based clinical-stage company advancing T cell vaccines and using its proprietary ATLAS™ platform to profile immune responses. Its lead programs are GEN-003, a therapeutic vaccine candidate for HSV-2, and GEN-004, a preclinical vaccine candidate against Streptococcus pneumoniae. The company also plans to expand its malaria program in collaboration with the Bill & Melinda Gates Foundation to identify antigens for a potential protein subunit vaccine. Genocea intends to use proceeds from the financing to continue development of its lead programs and to support ATLAS-based antigen discovery. The company is led by CEO Chip Clark and focuses on translating T cell profiling into vaccine candidates. Financially, Genocea reported the recent Series C and cumulative equity financing totals in the related announcement. Genocea is a Cambridge, MA-based biotechnology company developing a new class of T cell–based vaccines. Its lead program is a therapeutic vaccine for herpes simplex virus type 2 (HSV-2) infections. The company also maintains a deep research pipeline with prophylactic vaccine programs addressing Chlamydia trachomatis, Streptococcus pneumoniae, HSV-2 and Plasmodium falciparum (malaria). Genocea intends to use the proceeds from the financing to support clinical development of its lead HSV-2 program. The funds will also advance its broader research pipeline and associated programs. The company strengthened its leadership team concurrent with the financing, adding a new board member and a chief medical officer to oversee clinical, medical and regulatory activities.

Total raised

$65M

Funding rounds

2

Latest round

Series C

Latest activity

Oct 2012